Search results
Results from the WOW.Com Content Network
Obinutuzumab is recently reported to be safe and effective in some autoimmune diseases affecting the kidneys. It is a promising treatment of renal diseases with proteinuria, in particular patients with resistance or partial response to rituximab. [ 10 ]
An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help lower their stroke and heart attack risk, a new study has found.
Tesevatinib (KD019, XL647) is an experimental drug proposed for use in kidney cancer and polycystic kidney disease.The drug was first developed by Exelixis, Inc. [1] and was later acquired by Kadmon Corporation.
Genentech's Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer Phase III data from the CLL11 study to ...
Myelosuppression, diarrhoea, kidney failure, hypersensitivity, severe GI reactions (including perforation, ileus, colitis, etc.; all rare) and peripheral neuropathy Docetaxel: IV: As above. Breast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell head and neck cancer and gastric cancer.
Chronic kidney disease is a common complication for people living with type 2 diabetes. Diabetes is the leading cause of kidney failure, which is one of the leading causes of death in the US and ...
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
To treat Alzheimer's disease [4] Miglustat: Nedosiran: To lower urinary oxalate levels in primary hyperoxaluria type 1 and relatively preserved kidney function [4] Nirogacestat: To treat desmoid tumors [4] Pembrolizumab: Sutimlimab: Talquetamab: To treat relapsed or refractory multiple myeloma after at least four therapies [4] Toripalimab